The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
 
Lisa A. Kottschade
Consulting or Advisory Role - Array BioPharma; Bristol Myers Squibb (Inst); Immunocore; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Honoraria - AstraZeneca; AstraZeneca
Consulting or Advisory Role - Merck; Profound Medical; Takeda
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Evidio Domingo-Musibay
Honoraria - Regeneron
Consulting or Advisory Role - Castle Biosciences; Sanofi/Regeneron
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Clinigen Group (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst)
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Tizona Therapeutics, Inc. (Inst); US Oncology (Inst)
 
Brendan D. Curti
Honoraria - Clinigen Group; Nektar
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Galectin Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Agonox
 
Sarah Schober
No Relationships to Disclose
 
Mohammed M. Milhem
Consulting or Advisory Role - Exicure
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Matthew Stephen Block
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Immune Design (Inst); Marker, Inc. (Inst); Merck (Inst); Pharmacyclics (Inst); Sorrento Therapeutics (Inst); TILT Biotherapeutics; Transgene (Inst)
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Robert R. McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)